🌍 world

ADHD in 2026: Medication Shortages, New Drugs, Old Stigma

Over 22 million Americans now live with diagnosed ADHD, but a medication shortage that started in 2022 still haunts pharmacy shelves. Meanwhile, the FDA just approved a first-in-class triple reuptake inhibitor, and a British documentary calling ADHD a myth triggered a fierce backlash. The condition has never been more visible or more misunderstood.

Fact checked - 16 claims 26 Aug 2026 · 13 with sources

The ADHD landscape in August 2026 is defined by three colliding forces: unprecedented diagnostic rates, a medication supply crisis that refuses to die, and public controversies that threaten to undo decades of destigmatization work. As of 2022, approximately 11.4% of children aged 3 to 17 have ever received an ADHD diagnosis in the United States, representing about 7 million kids. Boys are diagnosed nearly twice as often as girls (15.6% versus 8.2%). Among adults, roughly 15.5 million Americans carried a current ADHD diagnosis by late 2023, with more than half diagnosed in adulthood rather than childhood. Put those numbers together and you're looking at over 22 million diagnosed Americans, with likely millions more undiagnosed. Teens aged 12 to 17 remain the most diagnosed age group as of May 2026. The increase is dramatic: between 2016 and 2022 alone, pediatric diagnoses rose by 1 million children. Researchers attribute the surge primarily to greater awareness and improved screening rather than an actual epidemic of new cases, though debates persist about whether modern environments (phones, processed food, rigid schooling) are genuinely worsening attention problems. But getting diagnosed is one thing. Getting treated is another nightmare entirely. The ADHD medication shortage that began in October 2022 when Teva, the largest U.S. manufacturer of mixed amphetamine salts (Adderall), hit manufacturing delays has now stretched past three and a half years. As of July 2026, stimulant shortages continue across many parts of the United States. Generic Adderall and several mixed amphetamine salts remain difficult to obtain in many regions. Extended-release methylphenidate products including generic Concerta and Ritalin LA are still on the FDA shortage list, with availability that comes and goes unpredictably. Generic lisdexamfetamine (the generic version of Vyvanse) also faces intermittent shortages, though brand-name Vyvanse remains more consistently available. The FDA's official drug shortage database as of mid-2026 still lists multiple ADHD stimulant formulations, with manufacturer-reported reasons including demand increases, active ingredient shortages, and manufacturing delays. The shortage is patchy and maddening: some products and strengths fill without trouble, while others vanish for weeks and reappear without warning. Nearly 2 million children with ADHD (30.1%) received no treatment in 2022, up significantly from 23% in 2016. Medication use among children with current ADHD actually declined from 62% in 2016 to 53.6% in 2022, despite growing diagnosis rates. The regulatory picture adds complexity: COVID-era telemedicine prescribing flexibilities for controlled substances have been extended a fourth time through December 31, 2026, but no final permanent telemedicine prescribing rule exists. The DEA sets annual production quotas for Schedule II stimulants, and that quota system has been blamed by manufacturers for insufficient supply, while the DEA insists manufacturers already have enough raw ingredients. Against this chaotic backdrop, the FDA approved centanafadine (brand name Simtriyo) on July 24, 2026, as the first and only norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) for ADHD in adults and children aged 6 and older weighing at least 20 kilograms. Traditional ADHD medications primarily target dopamine and norepinephrine, but centanafadine adds serotonin into the mix, offering a genuinely novel mechanism. The approval was based on four Phase 3 clinical trials involving children, adolescents, and adults, showing statistically significant improvements in ADHD symptoms compared to placebo. Post-hoc analyses suggested improvements beyond core attention and hyperactivity symptoms, including gains in executive functioning and emotional regulation. The drug is a once-daily extended-release capsule and a CNS stimulant, though early data suggests low potential for dependence and abuse. Simtriyo is expected to become available later in 2026 following DEA scheduling. Other treatment frontiers are opening as well. A massive November 2025 study from the University of Southampton confirmed that medication remains the most reliable ADHD treatment option for both children and adults. Researchers at Rockefeller University discovered in late 2025 that lowering certain versions of the Homer1 gene improved focus in mice by calming neural noise rather than increasing stimulation, potentially inspiring a new class of treatments. A 2026 JAMA Psychiatry study analyzed brain scans from 1,831 participants and identified three distinct ADHD subtypes, each rooted in different brain regions with potentially different treatment needs. The implication: the frustrating trial-and-error many families experience when finding the right medication may reflect real biological mismatches, not bad luck. Then came the controversy. On August 18, 2026, Channel 4 in the United Kingdom broadcast a documentary titled The Great ADHD Myth, hosted by NHS psychiatrist Dr. Max Pemberton, who concluded that ADHD is a social construct, not a disorder of the brain. The program featured medical experts skeptical of ADHD and the way it is treated, and questioned whether powerful psychiatric drugs should be given to so many children. ADHD UK, a prominent charity, filed a complaint with media regulator Ofcom, stating clearly: ADHD is not a myth and not a social construct. On August 19, 2026, the Royal College of Psychiatrists issued a statement emphasizing that research suggests 3% to 5% of the population have ADHD, indicating the condition is still under-recognized, under-diagnosed, and under-treated in the UK. The College's president warned that the way we speak about neurodevelopmental conditions can fuel harmful stigma and discourage people from seeking support and treatment. Channel 4 defended the program, saying there is considerable public debate on various aspects of ADHD and it is legitimate for that debate to be explored. The controversy erupted across social media, with many in the ADHD community expressing outrage that their lived experiences were being invalidated on national television. Workplace accommodations for adults with ADHD have become a major focus in 2026. Under the Americans with Disabilities Act (ADA), ADHD qualifies as a disability when it substantially limits major life activities like concentrating, thinking, organizing, and communicating. Adults with ADHD have legal rights to reasonable accommodations, which can include quiet workspaces or noise-blocking headphones, flexible scheduling, written instructions and training materials, time management tools, task breakdown into smaller chunks, extended deadlines, and altered work hours to match peak focus periods. Research shows ADHD symptoms can lead to poorer work performance, higher turnover, and higher unemployment rates compared to peers. With effective accommodations, however, employees often see improvements in productivity, confidence, and job satisfaction. Despite these protections, many adults with ADHD still struggle to disclose their diagnosis or request accommodations due to stigma and fear of discrimination.

My Take

Let's be blunt: if you can't consistently fill a prescription for a condition affecting 22 million Americans, your pharmaceutical supply chain is broken. The fact that the Adderall shortage has dragged on for nearly four years while regulators and manufacturers point fingers at each other is a policy failure of staggering proportions. The DEA's quota system for controlled substances made sense in the opioid crisis era, but it's now punishing millions of people who rely on stimulants to function at school and work. Meanwhile, parents are calling pharmacy after pharmacy, adults are rationing pills, and nearly a third of diagnosed kids are going completely untreated. This isn't a supply hiccup. It's a crisis that's become normalized. The approval of centanafadine is genuinely exciting science, offering a new mechanism that could help people who haven't responded to traditional stimulants or non-stimulants. The promise of targeting serotonin alongside dopamine and norepinephrine, with potential benefits for executive function and emotional regulation, could be transformative for a subset of patients. But let's not pretend a shiny new drug solves the access problem when people can't even get generics that have existed for decades. The pharmaceutical industry loves launching premium-priced novel agents while the basics remain unavailable. As for the Channel 4 documentary calling ADHD a myth: this is exactly the kind of irresponsible garbage that sets public health back by years. Framing a well-documented neurodevelopmental disorder as a social construct isn't brave contrarianism. It's denialism dressed up as debate, and it gives cover to every employer, teacher, and family member who wants to dismiss someone's struggles as laziness or poor discipline. Yes, there are legitimate conversations to be had about overdiagnosis in certain demographics, about the influence of pharmaceutical marketing, about whether our education systems and workplaces should be more flexible. But you don't start that conversation by platforming doctors who claim the condition itself doesn't exist while millions of people are fighting for recognition and treatment. The ADHD community deserves better than to have their reality questioned for ratings.

What Happens Next

Simtriyo (centanafadine) will likely hit pharmacy shelves by late 2026 once the DEA completes its scheduling process. Expect aggressive marketing from Otsuka Pharmaceutical positioning it as a breakthrough for patients who haven't responded well to traditional stimulants or who struggle with emotional dysregulation alongside attention symptoms. Insurance coverage will be the battleground: insurers typically require failures on multiple generic options before approving expensive new agents, but the ongoing generic shortages may actually speed prior authorization approvals. Watch for real-world effectiveness data over the next 12 to 18 months, particularly whether the serotonin component delivers meaningful benefits beyond what existing medications provide, or whether this turns out to be incremental improvement marketed as revolution. The medication shortage will probably persist through 2027 unless the DEA significantly raises production quotas or Congress intervenes with legislation. Some manufacturers have reported improved production capacity, but the fundamental tension between controlled substance quotas and surging demand remains unresolved. Expect continued patchwork availability, with patients and providers developing workarounds like switching between therapeutically equivalent formulations, splitting higher-dose tablets, or using brand-name products when generics are unavailable. The political pressure is building: patient advocacy groups are increasingly vocal, and this could become a 2028 election issue if the shortage stretches into a sixth year. The Channel 4 documentary backlash will likely result in an Ofcom investigation, though British media regulators historically give wide latitude to controversial programming in the name of editorial independence. More importantly, the incident reveals that ADHD stigma remains alive and well in mainstream media, particularly in the UK where diagnostic rates and treatment access lag behind the United States. Expect the ADHD advocacy community to remain mobilized, demanding more responsible coverage and pushing back harder against any future programming that questions the legitimacy of the condition. The research community may respond with renewed efforts to communicate brain imaging and genetic findings to the public, trying to cement the biological basis of ADHD in the public consciousness before misinformation takes deeper root.

What History Tells Us

ADHD has been described in medical literature since the early 20th century under various names (hyperkinetic disorder, minimal brain dysfunction), but it only gained its current diagnostic framework in the 1980s when it was formally defined in the DSM-III. Stimulant treatment dates back even further: amphetamines were first used to treat behavioral problems in children in 1937, and methylphenidate (Ritalin) was approved in 1955. The diagnostic criteria have been progressively broadened, particularly with the DSM-IV in 1994 recognizing inattentive presentations alongside hyperactive-impulsive types, which led to a surge in diagnoses particularly among girls and adults who had been missed under earlier, narrower criteria. The current medication shortage echoes earlier drug shortages in the 2010s but is unprecedented in duration and scope. The controversy over whether ADHD is real or overdiagnosed is also not new: the 1990s and 2000s saw heated debates about whether Ritalin was being overprescribed to control normal childhood behavior, with critics arguing that pharmaceutical companies were medicalizing ordinary temperamental variation. What's different in 2026 is that ADHD has simultaneously become more accepted in progressive circles (where neurodiversity frameworks celebrate different cognitive styles) while remaining deeply stigmatized in conservative and contrarian spaces (where it's dismissed as an excuse for poor discipline or parenting). The Channel 4 documentary represents the latter tradition, resurrecting arguments that many thought had been settled by decades of neuroimaging and genetic research.